ArticleThe oncologist2025
Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumors: a 102-case retrospective study.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thymic neuroendocrine tumours: molecular landscape, immune microenvironment and therapeutic perspectives.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Real-world application of surufatinib in the treatment of neuroendocrine tumors: a multi-center retrospective study in China.European journal of medical research · 2025Observational
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
introduction or hypothesisThe SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared with placebo. However, there is a lack of sufficient retrospective data on surufatinib's efficacy in treating thymic neuroendocrine tumors (TNETs). This study aimed to evaluate the efficacy and safety of surufatinib in well-differentiated TNETs by conducting a single center retrospective analysis.
methodsWe conducted a retrospective study at Fudan University Shanghai Cancer Center, including 102 patients with TNETs. This study assessed the efficacy and safety of surufatinib in this population.
resultsMedian progression-free survival was 10.0 months, ORR was 5.6%, and DCR was 83.1%. Surufatinib performed better in first-line treatment compared to secondary treatment in terms of ORR, DCR, and mPFS. The most common adverse events were diarrhea (15.7%), hypertension (19.1%), proteinuria (13.5%), and hypothyroidism (5.6%). About 33.3% of patients required dosage reduction from 300 mg/day to 200 mg/day (or 250 mg/day) due to adverse events, which in most cases were mitigated or disappeared with dose reduction.
conclusionsFor patients with advanced, progressive, well-differentiated TNETs, Surufatinib can be used as an option with a high mPFS and DCR. Moreover, the safety profile of surufatinib was found to be acceptable. These findings suggest that surufatinib could potentially serve as an innovative therapeutic option for this particular patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.